Lux Biosciences, Inc. Employee Directory
Biotechnology ResearchUnited States2-10 Employees
Lux Biosciences, Inc. is a privately held biotechnology company based in the United States that focuses on developing therapies for ophthalmic diseases. Its submission-stage program LUVENIQ is an oral formulation of voclosporin, a next-generation calcineurin inhibitor. Positive phase 3 results have been reported for the treatment of sight-threatening non-infectious uveitis, and Lux Biosciences collaborates with Isotechnika Pharma, which invented the molecule and pursues development for other indications. The company's activities place it in the biotechnology research sector, with a focus on addressing ocular inflammatory conditions. The collaboration with Isotechnika Pharma reflects an approach that relies on established science while pursuing additional indications for the molecule.